{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009609","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.069057+00:00","generated_at":"2026-05-15T09:18:52.719924+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioCardia reports 2025 net loss $8.2M; cash $2.5M; regulatory milestones for CardiAMP anticipated","bullets":["Net loss $8.2M (2025) vs $7.9M (2024); revenue $0; cash $2.5M at year-end.","R&D expenses $5.0M (+$0.6M YoY) due to CardiAMP HF trial closeout and Japan regulatory work.","CardiAMP HF II trial enrolling at 4 sites; Yale echo data showed reduced LV remodeling in treated patients.","FDA Q-Sub on CardiAMP approval pathway expected Q1 2026; Japan PMDA formal consultation Q2 2026.","Helix delivery system Pre-Submission accepted by FDA; meeting with CDRH/CBER scheduled Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009609","json":"https://secwatch.observer/filing/0001437749-26-009609.json","markdown":"https://secwatch.observer/filing/0001437749-26-009609.md","text":"https://secwatch.observer/filing/0001437749-26-009609.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774926009609/0001437749-26-009609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774926009609/bcda20260324_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:18:52.719924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}